Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
November 15, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock code: 600276 Stock abbreviation: Hengrui Pharma No.: Lin 2026-178

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement on the Inclusion of Company's Drugs in the National Reimbursement Drug List (NRDL) of China

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

In accordance with the Notice on Issuing the *Drug Catalog for National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance (2026)* (hereinafter referred to as "National Reimbursement Drug List (NRDL)") jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, some drugs of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereafter referred to as "Hengrui" or the "Company") have been included in the NRDL.

Through negotiations with the National Healthcare Security Administration regarding inclusion into the NRDL, Zeprumetostat Tablets, Ruzinurad Sodium Tablets, and Henagliflozin/Retagliptin/Metformin Sustained-Release Tablets (II) were included in the National Reimbursement Drug List (NRDL) for the first time. A new indication for Trastuzumab Rezetecan for Injection was successfully included in the NRDL. Dalpiciclib Isethionate Tablets were successfully renewed and included with new indications in the NRDL. Henagliflozin Proline Tablets, Rezvilutamide Tablets, Tegileridine Fumarate Injection, Oteseconazole Capsules, Henagliflozin/Metformin Sustained-Release Tablets (I)/(II), Camrelizumab for Injection, and Pregabalin

Sustained-Release Tablets were successfully renewed and retained in the NRDL. The details are as follows:

I. Drugs included in the NRDL

No.	Common Name of Drug	Dosage Form	Indication	Market Entry Time	Type of Adjustment
1	Zeprumetostat Tablets	Tablets	This product is indicated for adult patients with relapsed or refractory peripheral T-cell lymphoma who have received at least one prior line of systemic therapy.	August 2025	First inclusion
2	Ruzinurad Sodium Tablets	Tablets	This product is indicated for patients with gout and hyperuricemia.	May 2026	First inclusion
3	Henagliflozin/Retagliptin/Metformin Sustained-Release Tablets (II)	Tablets	This product is used, in conjunction with diet control and exercise, to improve glycemic control in adults with type 2 diabetes who have poor glycemic control after treatment with metformin hydrochloride.	October 2025	First inclusion
4	Trastuzumab Rezetecan for Injection	Injection	1. This product as monotherapy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have received at least one prior systemic therapy. 2. This product is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 therapies.	May 2025	New indication added (Item 2)
5	Dalpiciclib Isethionate Tablets	Tablets	1. This product is indicated for patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor as initial endocrine therapy; or in combination with fulvestrant in patients who have progressed after prior endocrine therapy. 2. This product, in combination with	December 2021	Renewal and new indication added (Item 2)

			endocrine therapy, is indicated for adjuvant treatment in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence.		
6	Henagliflozin Proline Tablets	Tablets	This product is indicated for improvement of glycemic control in adult patients with type 2 diabetes mellitus. 1. Monotherapy: This product as monotherapy, in conjunction with diet and exercise, can improve glycemic control in adult patients with type 2 diabetes mellitus. 2. This product is used in combination with metformin hydrochloride: This product can be used in combination with metformin hydrochloride, in conjunction with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus when adequate glycemic control is not achieved with metformin hydrochloride monotherapy. 3. Use in combination with metformin hydrochloride and retagliptin phosphate: This product can be used in combination with metformin hydrochloride and retagliptin phosphate, in conjunction with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus when adequate glycemic control is not achieved with metformin hydrochloride monotherapy.	December 2021	Renewal
7	Rezvilutamide Tablets	Tablets	This product is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who have a high tumor burden.	June 2022	Renewal

8	Tegileridine Fumarate Injection	Injection	This product is indicated for the treatment of moderate to severe postoperative pain.	January 2024	Renewal
9	Oteseconazole Capsules	Capsules	This product is indicated for the treatment of severe vulvovaginal candidiasis (VVC).	June 2023	Renewal
10	Henagliflozin/Metformin Sustained-Release Tablets (I)/(II)	Tablets	This product, in conjunction with diet control and exercise, is indicated for the improvement of glycemic control in adult patients with type 2 diabetes mellitus who are candidates for treatment with henagliflozin proline and metformin hydrochloride.	December 2023	Renewal
11	Camrelizumab for Injection	Injection	1. This product is indicated for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib and/or lenvatinib therapy and/or oxaliplatin-containing systemic chemotherapy. 2. This product, in combination with pemetrexed and carboplatin, is indicated for the first-line treatment of epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK)-negative unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). 3. This product is indicated for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose disease progressed after first-line chemotherapy or who are intolerant to chemotherapy. 4. This product is indicated for the treatment of patients with advanced nasopharyngeal carcinoma whose disease progressed after second-line or later chemotherapy or who are intolerant to chemotherapy. 5. This product, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment in patients with locally recurrent or metastatic nasopharyngeal carcinoma.	May 2019	Renewal

			6. This product, in combination with paclitaxel and cisplatin, is indicated for the first-line treatment in patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma. 7. This product, in combination with paclitaxel and carboplatin, is indicated for the first-line treatment in patients with locally advanced or metastatic squamous non-small cell lung cancer. 8. This product, in combination with rivoceranib, is indicated for the first-line treatment in patients with unresectable or metastatic hepatocellular carcinoma. 9. This product, in combination with famitinib malate, is indicated for patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy but have not received bevacizumab treatment.		
12	Pregabalin Sustained-Release Tablets	Tablets	For the treatment of postherpetic neuralgia.	September 2021	Renewal

II. Impact on the Company

The total sales of the Company's above-mentioned drugs were approximately CNY 6.95 billion in 2025, and approximately CNY 6.86 billion in the first three quarters of 2026. The inclusion of the Company's above-mentioned drugs into the NRDL will facilitate their sales, while its impact on the Company's business performance cannot be estimated for the time being. The NRDL (2026) will be officially implemented from January 1, 2027. The payment standards, reimbursement details, and other related information for medical insurance shall be subject to the official announcements from the National Healthcare Security Administration and other relevant government authorities. Investors are kindly advised to invest prudently, paying attention to prevent the risks involved.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

November 15, 2026